Market News & Trends
Catalent & Grünenthal Announce Successful Collaboration to Facilitate Expedited Clinical Development Timelines
Catalent and Grünenthal recently announced their successful formulation design and clinical-phase manufacturing collaboration for an orally dosed small molecule in Grünenthal's pipeline. Positive preclinical results…
Owlstone Medical Enters Partnership With Bicycle Therapeutics for the Development of Antigen-Targeted EVOC Probes for Early Cancer Detection
Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine, recently announced it has entered into a Research Agreement with Bicycle Therapeutics plc, a biotechnology company pioneering a new….
Roivant Reports Positive Topline Results From Phase 3 Trial of VTAMA (tapinarof) Cream, 1% Once Daily in Adults & Children as Young as 2
Dermavant Sciences, a Roivant Sciences (Nasdaq: ROIV) company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, recently announced positive results from ADORING 2, one…
Pfizer Invests $43 Billion in Seagen Acquisition to Battle Cancer
Pfizer Inc. and Seagen Inc. recently announced they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for $229 in cash….
Nemera & Nelson Labs Europe Strengthen Partnership to Offer Integrated Services to Customers
This strategic alliance will give a unique advantage to pharmaceutical & bio-tech customers – accelerating the go-to-market of their drug-device combination products by offering analytical chemistry, drug compatibility lab testing and expert advice….
Ajinomoto Bio-Pharma Services Awarded Three CDMO Leadership Awards
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, received three CDMO Leadership Awards in the categories Capabilities, Compatibility, and Expertise…
Immutep Announces Initiation of Phase 2/3 Trial for Eftilagimod Alpha Plus Paclitaxel in Metastatic Breast Cancer
Immutep Limited recently announced the initiation of AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and PAClitaxel), an integrated Phase 2/3 trial to evaluate eftilagimod alpha (efti) in combination…
Proteovant Therapeutics to Present Preclinical Data From Estrogen Receptor & IKZF2 Protein Degrader Programs
Proteovant Therapeutics, a Roivant Sciences (Nasdaq: ROIV) company leveraging the process of protein degradation to discover and develop transformative medicines for the treatment of patients…
Pii Announces New Vice President of Sales
Pharmaceutics International, Inc. (Pii) recently announced John Phillips has joined the company as Vice President of Sales. Mr. Phillips brings a wealth of almost 30…
Cingulate & Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate
Cingulate Inc. and Indegene recently announced a joint commercialization agreement to provide commercial support for Cingulate’s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment….
Atavistik Bio Announces Publication Describing Foundational Technology for its AMPS Platform
Atavistik Bio recently announced a new publication in the journal Science by Atavistik Bio co-founder Jared Rutter, PhD, describing the foundational technology upon which the…
Aenova Introduces New Sterile Strategy
Aenova Group, a leading international contract developer and manufacturer for the pharmaceutical and healthcare industries, presents its new sterile strategy…..
Nemera Reinforces Commitment to Sustainability With First Integrated ESG Report
Designed as a snapshot of work over the years and a look into the future, the first ESG report is a new and important step…
First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
First Wave BioPharma, Inc. recently announced that the first patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of….
Catalent Expands UpTempo AAV Platform to Accelerate Development of Gene Therapies
Catalent recently announced the expansion of its UpTempo platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors. The platform now includes an…
Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib
Sermonix Pharmaceuticals Inc. and Guardant Health, Inc. recently announced the initiation of a registrational Phase 3 clinical study comparing targeted lasofoxifene in combination with the…
Ribon Therapeutics Doses First Patient in Phase 1 Clinical Study for Patients With Moderate-to-Severe Atopic Dermatitis
Ribon Therapeutics recently announced dosing the first patient in the open-label cohort of patients with moderate-to-severe atopic dermatitis to measure the pharmacodynamic activity of RBN-3143…
QSAM Biosciences Receives FDA Clearance to Expand Enrollment Criteria in its Phase 1 Study Targeting Metastatic Bone Cancer
QSAM Biosciences Inc. recently announced US FDA has cleared the Company’s amended clinical trial protocol increasing the maximum age of participants to 75 years old…
Lonza Upgrades Powder Characterization Capabilities at Tampa Site
Lonza recently announced a significant enhancement to its powder characterization capabilities at its Small Molecules site in Tampa, FL. The facility has been upgraded to…
Evonik Opens New Facility for Pharmaceutical Lipids at Site in Germany
Evonik is opening a new GMP facility to manufacture lipids for advanced, pharmaceutical drug delivery applications. The lipid launch facility is located at the company’s site in Hanau, Germany and….